Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Reviews Samsung Bioepis’ Bevacizumab

Avastin Rival Will Be Sold Through Merck, Sharp & Dohme

Executive Summary

Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.

You may also be interested in...



Amneal Takes A Step Forward On Biosimilars

The FDA’s acceptance of Amneal’s filing for bevacizumab brings the company a step closer to its goal of launching a US biosimilar every year to 2023.

Merck & Co Puts A Date On Spinning Off Biosimilars

Merck & Co has disclosed more precise details around plans to spin off its more mature products, including biosimilars, into a new publicly traded company.

Bio-Thera Follows EU Bevacizumab Biosimilar Filing With FDA Goal Date

China’s Bio-Thera is continuing its journey to bring biosimilars to patients across the globe, with its BAT1706 biosimilar bevacizumab candidate accepted for filing by the US Food and Drug Administration.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel